+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. V. H-2 associativity of variant-specific antigens



Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. V. H-2 associativity of variant-specific antigens



European Journal of Immunology 12(11): 905-908



By in vitro mutagenesis of [mouse] mastocytoma P815, tumor cell variants that are rejected by syngeneic mice (tum-) were obtained. Most of these variants carry new individual antigens and stimulate a specific cytolytic T-cell (CTL) response in mixed leukocyte tumor cell culture (MLTC). The H-2 associativity of this response was examined for 6 different variants by measuring the inhibition of cell-mediated cytolysis by antibodies directed against products of the K or the D end of the H-2d complex. The lysis was either not inhibited (variants P91 and P116) or inhibited selectively by anti-Kd (variants P21, P32 and P198) or anti-Dd antibodies (variant P35). All these tum- variants expressed Kd and Dd antigens as measured by absorption of H-2 alloantisera. Long-term CTL clones can be obtained that are specific for individual tum- antigens. The pattern of H-2 associativity obtained with MLTC-derived CTL against 4 tum- variants was verified with CTL clones directed against the specific antigens of these variants. Concordant results were observed in all cases. In addition to CTL clones specific for tum- antigens, it is possible to isolate clones against a P815 tumor-associated antigen found on all P815 tum- variants. For these clones no clear associativity with either Kd or Dd products was found.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 043333056

Download citation: RISBibTeXText

PMID: 6818041

DOI: 10.1002/eji.1830121102


Related references

Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. IV. Analysis of variant-specific antigens by selection of antigen-loss variants with cytolytic T cell clones. European Journal of Immunology 12(5): 406-412, 1982

Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. VII. Dominant expression of variant antigens in somatic cell hybrids. Somatic Cell Genetics 9(3): 345-357, 1983

Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. I. Rejection by syngeneic mice. Journal of Experimental Medicine 152(5): 1175-1183, 1980

Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. Ii. T lymphocyte-mediated cytolysis. Journal of Experimental Medicine 152(5): 1184-1193, 1980

Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. III. Clonal analysis of the syngeneic cytolytic T lymphocyte response. European Journal of Immunology 12(5): 401-406, 1982

Immunogenic (tum-) variants obtained by mutagenesis of mouse mastocytoma P815. VIII. Detection of stable transfectants expressing a tum- antigen with a cytolytic T cell stimulation assay. Immunogenetics 26(3): 178-187, 1987

Immunogenic variants obtained by mutagenesis of mouse Lewis lung carcinoma. Recognition of variant-specific antigens by cytolytic T lymphocytes. European Journal of Cancer and Clinical Oncology 18(9): 867-874, 1982

Increased frequency of immunogenic variants obtained by repeated mutagen treatment of mouse mastocytoma P815. European Journal of Cancer and Clinical Oncology 19(11): 1529-1537, 1983

Immunogenic variants obtained by mutagenesis by mouse masto cytoma p 815 7. dominant expression of variant antigens in somatic cell hybrids. Somatic Cell Genetics 9(3): 345-358, 1983

Dissection of new antigens expressed on immunogenic variants of masto cytoma p 815 that were obtained by mutagenesis. Immunobiology 163(2-4): 144-145, 1982

Immunogenic variants obtained by mutagenesis of mouse masto cytoma p 815 6. occasional escape from host rejection due to antigen loss secondary variants. International Journal of Cancer 31(1): 119-124, 1983

Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis. Proceedings of the National Academy of Sciences of the United States of America 79(15): 4718-4722, 1982

Selection of highly transfectable variant from mouse mastocytoma P815. Somatic Cell and Molecular Genetics 11(5): 467-475, 1985

Protection against two spontaneous mouse leukemias conferred by immunogenic variants obtained by mutagenesis. Journal of Experimental Medicine 157(6): 1992-2001, 1983

Immunogenic variants obtained by mutagenesis of mouse masto cytoma p 815 2. t lymphocyte mediated cytolysis. Journal of Experimental Medicine 152(5): 1184-1193, 1980